Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Phase1 | Japan | NCT07340138 |
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase2 | Australia Canada China France Japan Netherlands South Korea Spain United States View all |
NCT07354074 |
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population |
Hidradenitis Suppurativa | Italy | NCT07543419 | |
REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria |
Paroxysmal Nocturnal Hemoglobinuria (PNH) | Italy | NCT07229235 | |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | Argentina Australia China India Malaysia South Korea Switzerland United States View all |
NCT07357727 |
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction |
Heart Failure With Reduced Ejection Fraction | Phase1 | Canada United States |
NCT07465653 |
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction |
Plaque, Atherosclerotic | Phase4 | China | NCT06372925 |
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy |
Secondary Malignancies of T-cell Origin | Japan | NCT07378969 | |
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) |
Cardiovascular Disease and Lipoprotein(a) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria Canada China Colombia Czechia Denmark France Germany Greece Hong Kong Hungary India Israel Italy Japan Netherlands Norway Poland Portugal Puerto Rico Romania Russia Slovakia South Africa South Korea Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT07517263 |
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China |
HR+/HER2- Advanced or Metastatic Breast Cancer | China | NCT07476170 |